Jonna Frasor

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5268870/publications.pdf

Version: 2024-02-01

39 papers	1,301 citations	361413 20 h-index	361022 35 g-index
39 all docs	39 docs citations	39 times ranked	2239 citing authors

#	Article	IF	Citations
1	Abstract P5-11-01: Identification of novel ER and ER-NFÎºB driven stem-like cell populations in ER+ breast cancer. Cancer Research, 2022, 82, P5-11-01-P5-11-01.	0.9	0
2	Selective pressure of endocrine therapy activates the integrated stress response through NFÎºB signaling in a subpopulation of ER positive breast cancer cells. Breast Cancer Research, 2022, 24, 19.	5.0	6
3	Ceramide-1-Phosphate Is Involved in Therapy-Induced Senescence. ACS Chemical Biology, 2022, 17, 822-828.	3.4	2
4	Endocrine Therapy-Resistant Breast Cancer Cells Are More Sensitive to Ceramide Kinase Inhibition and Elevated Ceramide Levels Than Therapy-Sensitive Breast Cancer Cells. Cancers, 2022, 14, 2380.	3.7	4
5	Estrogen Receptor-Regulated Gene Signatures in Invasive Breast Cancer Cells and Aggressive Breast Tumors. Cancers, 2022, 14, 2848.	3.7	1
6	Intestinal estrogen receptor beta suppresses colon inflammation and tumorigenesis in both sexes. Cancer Letters, 2020, 492, 54-62.	7.2	42
7	Update on the Role of NFÎºB in Promoting Aggressive Phenotypes of Estrogen Receptorâ€“Positive Breast Cancer. Endocrinology, 2020, 161, .	2.8	11
8	Cytoplasmic ERÎ± and NFÎºB Promote Cell Survival in Mouse Mammary Cancer Cell Lines. Hormones and Cancer, 2020, 11, 76-86.	4.9	8
9	The NF-ÎºB Pathway Promotes Tamoxifen Tolerance and Disease Recurrence in Estrogen Receptorâ€“Positive Breast Cancers. Molecular Cancer Research, 2020, 18, 1018-1027.	3.4	31
10	Editorial for Special Issue on â€œAlternative nuclear receptor ligandsâ€• Molecular and Cellular Endocrinology, 2019, 493, 110479.	3.2	0
11	Removal of Serum Lipids and Lipidâ€Derived Metabolites to Investigate Breast Cancer Cell Biology. Proteomics, 2019, 19, e1800370.	2.2	17
12	Structurally Diverse Histone Deacetylase Photoreactive Probes: Design, Synthesis, and Photolabeling Studies in Live Cells and Tissue. ChemMedChem, 2019, 14, 1096-1107.	3.2	6
13	A Cell-Permeable Stapled Peptide Inhibitor of the Estrogen Receptor/Coactivator Interaction. ACS Chemical Biology, 2018, 13, 676-684.	3.4	28
14	A Protective Role for Triacylglycerols during Apoptosis. Biochemistry, 2018, 57, 72-80.	2.5	43
15	Coactivation of Estrogen Receptor and IKKÎ² Induces a Dormant Metastatic Phenotype in ER-Positive Breast Cancer. Cancer Research, 2018, 78, 974-984.	0.9	34
16	Using Tumor Explants for Imaging Mass Spectrometry Visualization of Unlabeled Peptides and Small Molecules. ACS Medicinal Chemistry Letters, 2018, 9, 768-772.	2.8	7
17	Fatostatin induces pro- and anti-apoptotic lipid accumulation in breast cancer. Oncogenesis, 2018, 7, 66.	4.9	40
18	Histone deacetylase inhibitor-based chromatin precipitation for identification of targeted genomic loci. Journal of Biological Methods, 2018, 5, e88.	0.6	4

#	Article	IF	Citations
19	Racial disparity in survival from estrogen and progesterone receptor-positive breast cancer: implications for reducing breast cancer mortality disparities. Breast Cancer Research and Treatment, 2017, 163, 321-330.	2.5	34
20	A Novel Strategy to Co-target Estrogen Receptor and Nuclear Factor ÎºB Pathways with Hybrid Drugs for Breast Cancer Therapy. Hormones and Cancer, 2017, 8, 135-142.	4.9	6
21	Structural and Molecular Mechanisms of Cytokine-Mediated Endocrine Resistance in Human Breast Cancer Cells. Molecular Cell, 2017, 65, 1122-1135.e5.	9.7	99
22	Design, Synthesis, Molecular Modeling, and Biological Evaluation of Novel Amineâ€based Histone Deacetylase Inhibitors. ChemMedChem, 2017, 12, 2030-2043.	3.2	9
23	Divergent JNK Phosphorylation of HDAC3 in Triple-Negative Breast Cancer Cells Determines HDAC Inhibitor Binding and Selectivity. Cell Chemical Biology, 2017, 24, 1356-1367.e8.	5.2	27
24	Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells. Journal of Visualized Experiments, 2017, , .	0.3	5
25	Full antagonism of the estrogen receptor without a prototypical ligand side chain. Nature Chemical Biology, 2017, 13, 111-118.	8.0	48
26	Scaffold dependent histone deacetylase (HDAC) inhibitor induced re-equilibration of the subcellular localization and post-translational modification state of class I HDACs. PLoS ONE, 2017, 12, e0186620.	2.5	3
27	Knockout of the PHLDA1 gene in breast cancer cells reveals multiple roles for PHLDA1 in cancer phenotypes. FASEB Journal, 2017, 31, 178.8.	0.5	1
28	Dimethyl Fumarate Inhibits the Nuclear Factor ÎºB Pathway in Breast Cancer Cells by Covalent Modification of p65 Protein. Journal of Biological Chemistry, 2016, 291, 3639-3647.	3.4	107
29	A novel aspirin prodrug inhibits NFÎºB activity and breast cancer stem cell properties. BMC Cancer, 2015, 15, 845.	2.6	21
30	NFÎºB affects estrogen receptor expression and activity in breast cancer through multiple mechanisms. Molecular and Cellular Endocrinology, 2015, 418, 235-239.	3.2	46
31	Correlative Analysis of miRNA Expression and Oncotype Dx Recurrence Score in Estrogen Receptor Positive Breast Carcinomas. PLoS ONE, 2015, 10, e0145346.	2.5	16
32	CBP Mediates NF-ÎºB-Dependent Histone Acetylation and Estrogen Receptor Recruitment to an Estrogen Response Element in the BIRC3 Promoter. Molecular and Cellular Biology, 2012, 32, 569-575.	2.3	40
33	Minireview: Inflammation: An Instigator of More Aggressive Estrogen Receptor (ER) Positive Breast Cancers. Molecular Endocrinology, 2012, 26, 360-371.	3.7	149
34	Estrogen Promotes Breast Cancer Cell Survival in an Inhibitor of Apoptosis (IAP)-dependent Manner. Hormones and Cancer, 2010, 1, 127-135.	4.9	28
35	BindSDb: A binding-information spatial database. , 2010, , .		3
36	Proinflammatory Cytokines Enhance Estrogen-dependent Expression of the Multidrug Transporter Gene ABCG2 through Estrogen Receptor and NFÎºB Cooperativity at Adjacent Response Elements. Journal of Biological Chemistry, 2010, 285, 31100-31106.	3.4	86

#	Article	IF	Citations
37	Positive Cross-Talk between Estrogen Receptor and NF-Î¹B in Breast Cancer. Cancer Research, 2009, 69, 8918-8925.	0.9	131
38	Synergistic Up-Regulation of Prostaglandin E Synthase Expression in Breast Cancer Cells by 17Î²-Estradiol and Proinflammatory Cytokines. Endocrinology, 2008, 149, 6272-6279.	2.8	61
39	Prolactin regulation of estrogen receptor expression. Trends in Endocrinology and Metabolism, 2003, 14, 118-123.	7.1	97